Augmentation Strategies for Partial or Non-responders to Clozapine in Patients with Schizophrenia: A Bayesian Network Meta-analysis of Randomized Controlled Trials|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Clozapine is the only approved drug for treatment-resistant schizophrenia, but the response to the drug is often inadequate. Augmentation with other antipsychotics, anticonvulsants, and antidepressants is recommended for such patients, but there is a lack of evidence regarding the most effective therapy. This network meta-analysis was conducted to evaluate the efficacy of pharmacological agents used in the augmentation strategies in patients who were partial/non-responders to clozapine. Relevant data were extracted from 30 randomized controlled trials through searches of electronic databases (MEDLINE/PubMed, Embase, Cochrane, clinical trial registries). PRISMA guidelines were followed for the extraction, management, analysis, and reporting of the data. The outcome measure in this study was a reduction in symptom severity according to total PANSS/BPRS and was reported as the standardized mean difference with a 95% credible interval. Bayesian network meta-analysis with random effects model and uninformative priors was conducted, and the ranking probability of each intervention was done. Meta-regression was done to assess the effect of duration on the reduction in symptom severity scores. Mirtazapine (−5.2 [95%CrI: −7.7, −2.7]) and memantine (−2.1 [95%CrI: −4.0, −0.19]) were more efficacious than placebo for augmentation of clozapine in partial/non-responders and were the most effective adjunctive agents as per SUCRA scores. Both drugs did not cause a significant increase in frequency of adverse events compared to placebo. There was a significant effect of duration on the reduction in symptom severity. There was no evident publication bias. Mirtazapine and memantine may prove beneficial for augmentation of clozapine in non/partial responders to monotherapy.

번역하기

참고문헌 (Reference)

1 Meltzer HY, "Treatment-resistant schizophrenia--the role of clozapine" 14 : 1-20, 1997

2 Nucifora FC Jr, "Treatment resistant schizophrenia : clinical, biological, and therapeutic perspectives" 131 : 104257-, 2019

3 Muscatello MR, "Topiramate augmentation of clozapine in schizophrenia : a double-blind, placebo-controlled study" 25 : 667-674, 2011

4 Kane JM, "The role of clozapine in treatment-resistant schizophrenia" 73 : 187-188, 2016

5 Tiihonen J, "The efficacy of lamotrigine in clozapine-resistant schizophrenia : a systematic review and meta-analysis" 109 : 10-14, 2009

6 Zoccali R, "The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia : a double-blind, placebo-controlled study" 19 : 71-76, 2004

7 Zoccali R, "The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients : a double-blind, placebo-controlled study" 93 : 109-116, 2007

8 Hutton B, "The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions : checklist and explanations" 162 : 777-784, 2015

9 Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials" 343 : d5928-, 2011

10 Shiloh R, "Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A doubleblind, placebo-controlled study" 171 : 569-573, 1997